Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the use of topical finasteride from Hasson and Wong, with claims that none of their 800 users reported side effects. The user expresses skepticism about these claims and seeks others' experiences with the treatment.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.

A user is seeking advice on choosing the right topical finasteride for hair loss, considering different formats (spray, gel, aqueous solution) and brands (Xyon, Ro, Keeps, Hims Rx Hair Loss Serum, Happy Head Topical Rx Serum). They are also concerned about the optimal strength to minimize side effects while using it with topical minoxidil.

Treatments for hair loss, such as minoxidil, finasteride, and RU58841; humorous posts about hair loss; and the choice to stop using treatments in exchange for a different look.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

The user "OP" uses a combination of topical minoxidil 5%, finasteride 0.025%, and caffeine to combat hair loss, with noticeable results over 5-6 months. Side effects include unwanted body hair growth and an itchy scalp, but no significant sexual side effects.

Using a blunt tip syringe is an effective method for applying liquid topicals like minoxidil and RU58841, especially for those with thick or long hair experiencing diffuse thinning. The user found significant hair regrowth and increased density after using these topicals for less than three months.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

The conversation discusses using RU58841 or Pyrilutamide for hair loss, with some users suggesting switching to more proven treatments like oral or topical finasteride. One user reports no progress with RU58841, finasteride, and minoxidil, and mentions experiencing regression.

After 8 months of using topical finasteride, hair miniaturization continues, raising concerns about its effectiveness. Microneedling is suggested as a possible complementary treatment.

The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user seeks input from medical professionals and scientists on these treatments.

The conversation discusses alternative hair loss treatments beyond the commonly used Minoxidil and Finasteride. One user is trying diclofenac gel, caffeine + antioxidant serum, finasteride, ketoconazole shampoo, and has stopped using Minoxidil due to ineffectiveness, while another user has adopted lifestyle changes like exercise, diet, stress reduction, and topical caffeine, along with scalp massages and microneedling.

This conversation discusses the topical application of Minoxidil, with various users providing advice on how to accurately measure a dose and keep it from melting too quickly. Others have shared their experiences using oral finasteride for hair loss treatments.

The user humorously describes trying various hair loss treatments, including minoxidil, finasteride, and RU58841, with a satirical twist involving psychedelic experiences and imaginary entities. They mistakenly used LSD instead of RU58841 and plan to continue experimenting with other substances.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

User has been using topical finasteride and minoxidil since May, previously used a spray version since January. They are seeing vellus hairs and have added weekly microneedling to their routine.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

The conversation discusses various methods for applying topical minoxidil to the scalp, including using fingers, a shoe polish bottle, a dropper, a toothbrush, a q-tip, a makeup brush, and a syringe. Users emphasize the importance of massaging the product into the scalp for better absorption.